首页 > 市场调查报告书 > 製药

呼吸器

市场调查报告书

商品编码

1741400

Alpha-1 肺部疾病市场（依疾病类型、治疗类型、给药途径、通路及地区划分）

Alpha 1 Lung Disease Market, By Disease Type, By Treatment Type, By Route of Administration, By Distribution Channel, By Region

出版日期: 2025年03月27日 | 出版商:

Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3个工作天内

价格

简介目录

Alpha-1 肺部疾病市场规模预计在 2025 年为 70.5 亿美元，预计到 2032 年将达到 236.8 亿美元，2025 年至 2032 年的年复合成长率（CAGR）为 18.9%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	70.5亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	18.90%	2032年价值预测	236.8亿美元

α-1肺病是一种罕见的遗传性疾病，会影响肺部和肝臟。此病是由α-1抗胰蛋白酶（AAT）缺乏所引起，AAT是一种保护肺部免受损伤的蛋白质。这种疾病可能导致慢性阻塞性肺病（COPD）和肝病。

全球α-1型肺病市场的发展受到盛行率上升、医疗专业人员认知度提升、诊断技术进步的驱动。根据α-1基金会估计，美国和欧洲约有10万人被诊断为α-1型肺病。然而，实际患病人数据信件要高得多。

市场动态：

Alpha-1型肺部疾病市场的主要驱动力在于盛行率的上升。随着越来越多的患者被诊断出患有Alpha-1型肺部疾病，对有效治疗方案的需求也日益增长。这促使市场主要参与者加强研发力道。

然而，有几个因素制约了市场的成长：一般民众和医务人员对疾病的认识程度低，阻碍了早期诊断和治疗，治疗费用高以及某些地区缺乏报销政策，对市场成长构成了挑战。

儘管面临诸多挑战，市场仍蕴含着许多成长机会。基因检测等诊断技术的进步有望提高早期检测率。此外，新型治疗药物和标靶药物的开发也为α-1型肺病的治疗带来了希望。

例如，2022年6月，美国食品药物管理局（FDA）的药品评估与食品药物管理局中心（CDER）和生技药品评估与研究中心（CBER）——美国国家中心——将宣布计划与生物製药关键路径研究所（C-Path）合作，成立一个联盟，旨在开发适用于α-1抗胰蛋白酶缺乏症（AATD）临床开发项目，成立一个联盟，旨在开发适用于α-125,D55（AATD）临床开发项目，导致肺移植会导致肺臟移植会进行性破坏疾病，导致肺臟移植会导致肺臟移植会导致肺臟移植是一种罕见疾病，导致肺臟移植会导致肺臟移植会导致肺臟移植会导致肺臟移植会导致肺臟移植是一种罕见疾病（AATD）临床开发项目。

本研究的主要特点

本报告对全球 alpha-1 肺部疾病市场进行了详细分析，包括预测期 2025-2032 的市场规模和复合年增长率。
它揭示了各个领域的潜在收益成长机会，并说明了该市场引人注目的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
这项研究涉及的主要企业包括阿斯特捷利康、勃林格殷格翰国际有限公司、罗氏有限公司、诺华公司、辉瑞公司、默克公司、百时美施贵宝公司、武田製药有限公司、杰特贝林公司、Vertex Pharmaceuticals Incorporated、安进公司、赛诺菲公司、葛兰素史克公司、吉利德科学公司、艾伯维科公司等公司。
本报告的见解将帮助负责人和经营团队就未来的产品发布、产品类型升级、市场扩张和行销策略做出明智的决策。
全球 Alpha-1 肺部疾病市场报告针对该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员可以透过用于分析全球 Alpha-1 肺部疾病市场的各种策略矩阵来更轻鬆地做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 7.05 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	18.90%	2032 Value Projection:	USD 23.68 Bn

The global Alpha 1 Lung Disease market is driven by the increasing prevalence of the disease, growing awareness among healthcare professionals, and advancements in diagnostic techniques. According to the Alpha-1 Foundation, it is estimated that around 100,000 individuals in the U.S. and Europe have been diagnosed with Alpha 1 Lung Disease. However, the actual number of affected individuals is believed to be much higher.

Market Dynamics:

The market for Alpha 1 Lung Disease is primarily driven by the rising prevalence of the disease. As more individuals are being diagnosed with Alpha 1 Lung Disease, the demand for effective treatment options is increasing. This has led to a surge in research and development activities by key players in the market.

However, there are certain factors that restrain the growth of the market. Limited awareness about the disease among the general population and healthcare professionals hinders early diagnosis and treatment. Additionally, the high cost of treatment and lack of reimbursement policies in some regions pose challenges to market growth.

Despite these challenges, the market presents several opportunities for growth. Technological advancements in diagnostic techniques, such as genetic testing, are expected to improve early detection rates. Moreover, the development of novel therapies and targeted drugs holds promise for the treatment of Alpha 1 Lung Disease.

For instance, in June 2022, U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), the Center within the U.S. Food and Drug Administration (FDA) are pleased to announce their partnership with the Critical Path Institute (C-Path), a non-profit organization to initiate planning for a consortium aimed at developing tools appropriate for use in clinical development programs for alpha-1 antitrypsin deficiency (AATD), a rare disease causing progressive destruction of lung tissue leading to premature mortality or need for lung transplant.

Key Features of the Study:

This report provides an in-depth analysis of the global Alpha 1 Lung Disease market, including market size (US$ Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period 2025-2032
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
The key companies covered as a part of this study include AstraZeneca, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Merck & Co., Inc., Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited., CSL Behring, Vertex Pharmaceuticals Incorporated, Amgen Inc., Sanofi, GSK plc, Gilead Sciences, Inc., AbbVie Inc., and Regeneron Pharmaceuticals Inc.
Insights from this report would allow marketers and management authorities to make informed decisions regarding future product launches, type upgrades, market expansion, and marketing tactics
The global Alpha 1 Lung Disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Alpha 1 Lung Disease market

Alpha 1 Lung Disease Market Segmentation:

By Disease Type
- Alpha-1 Antitrypsin Deficiency
- Chronic Obstructive Pulmonary Disease (COPD)
- Pulmonary Fibrosis
- Bronchiectasis
- Others
By Treatment Type
- Augmentation Therapy
- Bronchodilators
- Corticosteroids
- Oxygen Therapy
- Lung Transplantation
- Others
By Route of Administration
- Injectable
- Oral
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- AstraZeneca
- Boehringer Ingelheim International GmbH
- F.Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc.
- Merck & Co., Inc.,
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company Limited.
- CSL Behring
- Vertex Pharmaceuticals Incorporated
- Amgen Inc.
- Sanofi
- GSK plc
- Gilead Sciences, Inc.
- AbbVie Inc.
- Regeneron Pharmaceuticals Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Alpha 1 Lung Disease, By Disease Type
- Market Alpha 1 Lung Disease, By Treatment Type
- Market Alpha 1 Lung Disease, By Route of Administration
- Market Alpha 1 Lung Disease, By Distribution Channel
- Market Alpha 1 Lung Disease, By Region
Coherent Opportunity Map (COaM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Rising Prevalence of COPD Globally
Increasing Diagnosis Rates
New Product Launches
Strong Pipeline of Drugs
- Restraints
Limited awareness about the disease among the general population
- Opportunities
Technological advancements in diagnostic techniques
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Alpha 1 Lung Disease Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Alpha 1 Lung Disease Market, By Disease Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Alpha-1 Antitrypsin Deficiency
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Chronic Obstructive Pulmonary Disease (COPD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Pulmonary Fibrosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Bronchiectasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Alpha 1 Lung Disease Market, By Treatment Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Augmentation Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Bronchodilators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Oxygen Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Lung Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

7. Alpha 1 Lung Disease Market, By Route of Administration, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

8. Alpha 1 Lung Disease Market, By Distribution Channel, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

9. Alpha 1 Lung Disease Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021-2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
  - South Africa
  - North Africa
  - Central Africa

10. Competitive Landscape

AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Takeda Pharmaceutical Company Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
CSL Behring
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Vertex Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
GSK plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Regeneron Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views

11. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

Alpha-1 肺部疾病市场（依疾病类型、治疗类型、给药途径、通路及地区划分）